Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials

PLoS Neglected Tropical Diseases

Volumn 10, Issue 7, 2016, Pages

  Harenberg, Anke ^a   de Montfort, Aymeric ^a   Jantet Blaudez, Frédérique ^a   Bonaparte, Matthew ^a   Boudet, Florence ^a   Saville, Melanie ^a   Jackson, Nicholas ^a   Guy, Bruno ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CYD TDV VACCINE; DENGUE VACCINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; CYTOKINE; LIVE VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENGUE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; VACCINATION; YELLOW FEVER VIRUS; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DENGUE VIRUS; FEMALE; GENETICS; HOSPITALIZATION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALE; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CYTOKINES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; VACCINES, ATTENUATED;

EID: 84980337096     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004830     Document Type: Article

References (35)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, (2013) The global distribution and burden of dengue. Nature496: 504–507. doi: 10.1038/nature1206023563266
2. WHO (2012) Global strategy for dengue and prevention and control 2012–2020.
3. Martina BE, Koraka P, Osterhaus AD, (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev22: 564–581. doi: 10.1128/CMR.00035-0919822889
4. Pancharoen C, Mekmullica J, Thisyakorn U, (2001) Primary dengue infection: what are the clinical distinctions from secondary infection?Southeast Asian J Trop Med Public Health32: 476–480. 11944702
5. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS, (2000) Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol28: 183–188. 10865168
6. Green S, Rothman A, (2006) Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis19: 429–436. 16940865
7. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM, (2006) Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg74: 142–147. 16407359
8. Suharti C, van Gorp EC, Dolmans WM, Setiati TE, Hack CE, Djokomoeljanto R, van der Meer JW, (2003) Cytokine patterns during dengue shock syndrome. Eur Cytokine Netw14: 172–177. 14656693
9. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF, (2008) Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis8: 86. doi: 10.1186/1471-2334-8-8618578883
10. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Lew R, Innis BL, Kurane I, Rothman AL, Ennis FA, (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis179: 755–762. 10068569
11. Rothman AL, (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol11: 532–543. doi: 10.1038/nri301421760609
12. Halstead SB, (2007) Dengue. Lancet370: 1644–1652. 17993365
13. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM, (2010) Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis10: 712–722. doi: 10.1016/S1473-3099(10)70166-320883967
14. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA, (2011) Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol85: 1671–1683. doi: 10.1128/JVI.00220-1021123382
15. Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS, Anderson R, Lin YS, (2013) Current progress in dengue vaccines. J Biomed Sci20: 37. doi: 10.1186/1423-0127-20-3723758699
16. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van d V, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet384: 1358–1365. doi: 10.1016/S0140-6736(14)61060-625018116
17. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes SM, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med372: 113–123. doi: 10.1056/NEJMoa141103725365753
18. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, (2015) Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med.
19. Oliveira-Pinto LM, Gandini M, Freitas LP, Siqueira MM, Marinho CF, Setubal S, Kubelka CF, Cruz OG, Oliveira SA, (2012) Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1beta and CCL2/MCP-1 in dengue fever and parvovirosis. Mem Inst Oswaldo Cruz107: 48–56. 22310535
20. Rathakrishnan A, Wang SM, Hu Y, Khan AM, Ponnampalavanar S, Lum LC, Manikam R, Sekaran SD, (2012) Cytokine expression profile of dengue patients at different phases of illness. PLoS One7: e52215. doi: 10.1371/journal.pone.005221523284941
21. Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, Aguirre E, Alvarez M, Volk HD, Guzman MG, (2010) MCP-1 and MIP-1alpha expression in a model resembling early immune response to dengue. Cytokine52: 175–183. doi: 10.1016/j.cyto.2010.06.01020650649
22. Semple JW, Italiano JE, Jr.Freedman J, (2011) Platelets and the immune continuum. Nat Rev Immunol11: 264–274. doi: 10.1038/nri295621436837
23. Singla M, Kar M, Sethi T, Kabra SK, Lodha R, Chandele A, Medigeshi GR, (2016) Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India-Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity. PLoS Negl Trop Dis10: e0004497. doi: 10.1371/journal.pntd.000449726982706
24. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF, (2014) Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis210: 558–566. doi: 10.1093/infdis/jiu08824526742
25. Ferreira RA, de Oliveira SA, Gandini M, Ferreira LC, Correa G, Abiraude FM, Reid MM, Cruz OG, Kubelka CF, (2015) Circulating cytokines and chemokines associated with plasma leakage and hepatic dysfunction in Brazilian children with dengue fever. Acta Trop149: 138–147. doi: 10.1016/j.actatropica.2015.04.02325944351
26. Butthep P, Chunhakan S, Yoksan S, Tangnararatchakit K, Chuansumrit A, (2012) Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. Pediatr Infect Dis J31: e232–e238. doi: 10.1097/INF.0b013e31826fd45622926216
27. Chareonsirisuthigul T, Kalayanarooj S, Ubol S, (2007) Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol88: 365–375. 17251552
28. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, Chen LC, Huang JH, Lam TM, Liu CC, Halstead SB, (2004) Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis189: 221–232. 14722886
29. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA, (1999) Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol59: 329–334. 10502265
30. Malavige GN, Gomes L, Alles L, Chang T, Salimi M, Fernando S, Nanayakkara KD, Jayaratne S, Ogg GS, (2013) Serum IL-10 as a marker of severe dengue infection. BMC Infect Dis13: 341. doi: 10.1186/1471-2334-13-34123883139
31. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, Rodriguez R, Rosario D, Martinez E, Denny T, Guzman MG, (2004) IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol73: 230–234. 15122797
32. Guy B, Jackson N, (2016) Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol14: 45–54. doi: 10.1038/nrmicro.2015.226639777
33. De La Cruz Hernandez SI, Puerta-Guardo H, Flores-Aguilar H, Gonzalez-Mateos S, Lopez-Martinez I, Ortiz-Navarrete V, Ludert JE, Del Angel RM, (2014) A strong interferon response correlates with a milder dengue clinical condition. J Clin Virol60: 196–199. doi: 10.1016/j.jcv.2014.04.00224793964
34. Srikiatkhachorn A, Green S, (2010) Markers of dengue disease severity. Curr Top Microbiol Immunol338: 67–82. doi: 10.1007/978-3-642-02215-9_619802579
35. John DV, Lin YS, Perng GC, (2015) Biomarkers of severe dengue disease—a review. J Biomed Sci22: 83. doi: 10.1186/s12929-015-0191-626462910